Entity Addresses, Address Type [Axis]
Business Contact [Member]
Revision of Prior Period [Axis]
Previously Reported [Member]
Product and Service [Axis]
Product [Member]
Service [Member]
License Royalty And Other [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Including Portion Attributable to Noncontrolling Interest [Member]
Class of Stock [Axis]
Common Class A [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Scenario [Axis]
Forecast [Member]
Segments [Axis]
Cell Therapy [Member]
Degenerative Disease [Member]
Biovance 3L [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Customer [Axis]
One Customer [Member]
Concentration Risk Benchmark [Axis]
Accounts Receivable [Member]
Concentration Risk Type [Axis]
Customer Concentration Risk [Member]
Customer A [Member]
Customer Two [Member]
Revenue Benchmark [Member]
Customer One [Member]
Long-Lived Tangible Asset [Axis]
Building [Member]
Office Equipment And Furniture [Member]
Furniture and Fixtures [Member]
Equipment [Member]
Computer Equipment [Member]
Software Development [Member]
Leasehold Improvements [Member]
Antidilutive Securities [Axis]
Share-Based Payment Arrangement, Option [Member]
Restricted Stock Units (RSUs) [Member]
Warrant [Member]
Convertible Debt Securities [Member]
Class of Warrant or Right [Axis]
GX Sponsor Warrants [Member]
May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Sanuwave Forbearance Agreement [Member]
Credit Facility [Axis]
Letter Agreement [Member]
Public Warrants [Member]
Sponsors Warrants [Member]
Two Thousand Twenty Three Registered Direct Warrants [Member]
May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member]
Measurement Input Type [Axis]
Measurement Input, Expected Dividend Rate [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Price Volatility [Member]
May Two Thousand Twenty Two Private Investmentin Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrants [Member]
Contingent Consideration by Type [Axis]
Contingent Stock Consideration [Member]
Lender Name [Axis]
Yorkville [Member]
Inventory [Axis]
Due To Lower Of Cost Or Market Adjustments For Work In Progress Goods [Member]
Due To Lower Of Cost Or Market Adjustments For Finished Goods [Member]
Laboratory And Production Equipment [Member]
Machinery Equipment And Fixtures [Member]
Construction in Progress [Member]
Other [Member]
Indefinite-Lived Intangible Assets [Axis]
In Process Research and Development [Member]
Cell Therapy Clinical Trial Update [Member]
Biobanking [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Developed Technology Rights [Member]
Customer Relationships [Member]
Trademarks and Trade Names [Member]
Reacquired Rights [Member]
Pre Paid Advance Agreement [Member]
Short-Term Debt, Type [Axis]
Convertible Promissory Notes [Member]
Equity Purchase Agreement [Member]
Debt Instrument [Axis]
Loan Agreement [Member]
Title and Position [Axis]
Chairman And Chief Executive Officer [Member]
Ceo Promissory Note [Member]
C V Starr Co Inc [Member]
Forbearance Agreement [Member]
Vesting [Axis]
Tranche Two Warrant [Member]
Bridge Loan [Member]
Initial Loan [Member]
Additional Loan [Member]
Tranche One Warrant [Member]
Initial And Second Tranche [Member]
Office Manufacturing And Laboratory Space [Member]
Geographical [Axis]
Florham Park New Jersey [Member]
Business Acquisition [Axis]
Legacy Celularity [Member]
Related and Nonrelated Parties [Axis]
H L I Cellular Therapeutics [Member]
Legacy Celularitys [Member]
Related Party Transaction [Axis]
L L C And Anthrogenesis [Member]
Counterparty Name [Axis]
Palantir Technologies Inc [Member]
Master Subscription Agreement [Member]
Statement of Income Location, Balance [Axis]
Software Cease Use Costs [Member]
License Agreement [Member]
Settlement and Release Agreement [Member]
Litigation Case [Axis]
Evolution [Member]
Preferred Stock [Member]
Sale of Stock [Axis]
Private Placement [Member]
May 2022 Private Investment In Public Equity Warrants Modified [Member]
April Two Thousand Twenty Three Registered Direct Warrants Modified [Member]
At the Market Sales Agreement [Member]
March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]
May Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]
Two Thousand Twenty Four Warrant Repricing [Member]
January Two Thousand Twenty Four Pipe Warrants [Member]
Chief Administrative Officer [Member]
Amended Employment Agreement [Member]
RWI Forbearance Agreement [Member]
May Two Thousand Twenty Two Private Investment In Public Equity Warrant [Member]
May Two Thousand Twenty Three Private Investment In Public Equity Warrant [Member]
Investor Rights Agreement [Member]
Dragasac Limited [Member]
March Two Thousand Twenty Three Loan Warrants [Member]
June Two Thousand Twenty Three Loan Warrants [Member]
Dragasac Warrant [Member]
Sponsor Warrants [Member]
March Two Thousand Twenty Three Private Investment in Public Equity Warrants, Modified [Member]
April Two Thousand Twenty Three Registered Direct Warrants [Member]
June Two Thousand Twenty Three Warrants [Member]
July Two Thousand Twenty Three Registered Direct Warrants [Member]
January 2024 Bridge Loan Tranche One Warrants [Member]
January Two Thousand Twenty Four Bridge Loan Tranche Two Warrants [Member]
March 2024 Rwi Forbearance Warrants [Member]
Starr Forbearance Agreement [Member]
Plan Name [Axis]
Two Thousand And Twenty One [Equity Incentive Plan [Member]
2017 Equity Incentive Plan [Member]
Award Type [Axis]
Awards With Performance Conditions [Member]
Initial Tranche [Member]
Second Tranche [Member]
Awards With Market Conditions [Member]
Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Payment Arrangement, Tranche Two [Member]
Performance Shares [Member]
Market Condition Stock Unit [Member]
Two Thousand And Twenty One And Two Thousand And Seventeen Equity Incentive Plan [Member]
2021 And 2017 Plan [Member]
Twenty Twenty One Plan [Member]
Cost of Sales [Member]
Research and Development Expense [Member]
Selling, General and Administrative Expenses [Member]
Regeneron Research Collaboration Services Agreement [Member]
Arthrex Agreement [Member]
Evolution Agreement [Member]
Pulthera Llc Binding Term Sheet [Member]
License Agreement With Biocellgraft Inc [Member]
Income Tax Jurisdiction [Axis]
United States Federal And State [Member]
Dr Robert Hariri [Member]
Securities Purchase Agreement [Member]
Dr Hariri [Member]
Consulting Agreement [Member]
Dr Andrew Pecora [Member]
Scientific And Clinical Advisor Agreement [Member]
Robin L Smith Md [Member]
Advisory Agreement [Member]
COTA Inc [Member]
Cryoport Systems Inc [Member]
CV Star Loan [Member]
Statement Equity Components Axis. [Axis]
Resorts World Inc Pte Ltd [Member]
Sorrento Therapeutics Inc [Member]
Ms Hariri [Member]
Employment Of Immediate Family Member [Member]
CV Starr Bridge Loan Net Of Discount [Member]
R W I Bridge Loan Net Of Discount [Member]
Asset Acquisition [Axis]
Sequence Lifescience Inc [Member]
Entity Addresses [Table]
Entity Addresses [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Contact Personnel Name
Statement [Table]
Statement [Line Items]
Assets
Current assets:
Cash and cash equivalents
Accounts receivable, net of allowance
Notes receivable
Inventory
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Goodwill
Intangible assets, net
Right-of-use assets - operating leases
Restricted cash
Inventory, net of current portion
Other long-term assets
Total assets
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
Accrued expenses and other current liabilities
Accrued R&D software
Short-term debt - Yorkville ($17,223 at fair value and $16,623 unpaid principal balance at December 31, 2023 and $37,603 at fair value and $37,000 unpaid principal balance at December 31, 2022)
Short-term debt - unaffiliated (includes debt measured at fair value of $3,695 at September 30, 2024 and $17,223 at December 31, 2023, respectively)
Other short-term debt
Short-term debt - related party
Short-term debt - related parties - C.V. Starr and RWI
Short-term debt - related parties
Deferred revenue
Total current liabilities
Deferred revenue, net of current portion
Acquisition-related contingent consideration
Noncurrent lease liabilities - operating
Warrant liabilities
Deferred income tax liabilities
Other liabilities
Total liabilities
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, value
Common stock, value
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance
Short-term debt, fair value
Short-term debt, unpaid principal balance
Preferred stock par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Revenues
Total net revenues
Operating expenses
Cost of revenues
Research and development
Software cease-use costs
Selling, general and administrative
Change in fair value of contingent consideration liability
Goodwill impairment
IPR&D impairment
Amortization of acquired intangible assets
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Change in fair value of warrant liabilities
Change in fair value of debt
Loss on debt extinguishment
Other expense, net
Total other income (expense)
Loss before income taxes
Income tax expense (benefit)
Net loss
Change in fair value of debt due to change in credit risk, net of tax
Other comprehensive (loss) income
Comprehensive loss
Net (loss) income per share - basic
Weighted average shares outstanding - basic
Net (loss) income per share - diluted
Weighted average shares outstanding - diluted
Balances
Balance, shares
Cumulative effect adjustment ASU 2016-02
Reclassification of previously exercised stock options
Reclassification of previously exercised stock options, shares
Exercise of stock options
Exercise of stock options, shares
Purchase and retirement of common shares
Purchase and retirement of common shares, shares
Exercise of warrants
Exercise of warrants, shares
Common stock issued pursuant to short-term debt conversion
Common stock issued pursuant to short-term debt conversion, shares
Vesting of restricted stock units
Vesting of restricted stock units, in shares
Tax withholding on vesting of restricted stock units
Tax withholding on vesting of restricted stock units, shares
Stock-based compensation expense
Issuance of common stock and warrants in PIPE Offering, net of offering expenses
Issuance of common stock and warrants in PIPE Offering, net of offering expenses, in shares
Issuance of common stock in ATM offering, net of commissions and offering expenses
Issuance of common stock in ATM offering, net of commissions and offering expenses, shares
Change in fair value of debt due to change in credit risk, net of tax
Net income (loss)
Issuance of common stock in Registered Direct Offering, net of offering expenses
Issuance of common stock in Registered Direct Offering, net of offering expenses, shares
Common stock issued pursuant to short-term debt maturity extension
Common stock issued pursuant to short-term debt maturity extension, shares
Fair value of warrant modification for professional services
Issuance of common stock for stem-cells to be used in research and development
Issuance of common stock for stem-cells to be used in research and development, shares
Issuance of warrants on senior secured bridge loan
Vesting of restricted stock units
Vesting of restricted stock units, shares
Issuance of common stock in PIPE Offering, net of offering expenses
Issuance of common stock in PIPE Offering, net of offering expenses, shares
Issuance of common stock under ATM Agreement
Issuance of common stock under ATM Agreement, shares
Issuance of warrants (C.V. Starr & RWI)
Issuance of common stock to Yorkville for debt extension and SEPA commitment fee
Issuance of common stock to Yorkville for debt extension and SEPA commitment fee, in shares
Issuance and modification of warrants to RWI and C.V. Starr
Issuance of warrants to Palantir as consideration for settlement agreement
Issuance of warrants to Palantir as consideration for settlement agreement, in shares
Retirement of shares in connection with reverse stock split
Retirement of shares in connection with reverse stock split, in shares
Reclassification of warrants from liability classified to equity classified
Balances
Balance, shares
Statement of Cash Flows [Abstract]
Cash flow from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Non cash lease expense
Deferred income taxes
Provision for credit losses
Provision for inventory obsolescence
Change in fair value of warrant liabilities
Inventory impairment
IPR&D impairment
Stock-based compensation expense
Change in fair value of contingent consideration
Acquired in-process research and development
Issuance of common stock for stem-cells to be used in research and development
Issuance of common stock to Palantir as consideration for settlement agreement
Issuance of common stock relating to Yorkville debt extension
Discounts arising from RWI loan arrangement - related party
Fair value of warrant modification for professional services
Change in fair value of debt
Change in fair value of contingent stock consideration
Other, net
Issuance of common stock to Yorkville for debt extension and SEPA commitment fee
Loss on extinguishment of debt
Non cash interest expense
Changes in assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other liabilities
Accrued R&D software
Right-of-use assets and lease liabilities
Lease liabilities - operating
Deferred revenue
Net cash used in operating activities
Cash flow from investing activities:
Capital expenditures
Proceeds from Sanuwave convertible note receivable
Purchase of acquired in-process research and development
Net cash provided by (used in) investing activities
Cash flow from financing activities:
Proceeds from RWI senior secured bridge loan and warrants - related party
Proceeds from warrants and short-term debt - related parties
Proceeds from issuance of short-term debt - unaffiliated
Principal payments of Yorkville short-term debt
Proceeds from issuance of senior secured C.V. Starr bridge loan and warrants - related party
Proceeds from short-term debt
Proceeds from the sale of common stock in ATM offering
Payments of ATM offering costs and commissions
Repayments of short-term debt - unaffiliated
Payment of SEPA commitment fee
Repayments of short-term debt - related parties
Proceeds from other short-term debt
Proceeds from other short-term debt - related party
Proceeds from PIPE financing
Proceeds from the exercise of stock options
Tax withholding on vesting of restricted stock units
Proceeds from registered direct offering
Payments of PIPE and other issuance costs
Net cash provided by financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses
Common stock issued for short-term debt conversion
Issuance of warrants on senior secured bridge loan
Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification
PIPE related offering costs included in accrued expenses
Interest accrued on senior secured loans within long-term debt - related parties
Reclassification of option liabilities to equity
Modification of C.V. Starr warrants in connection with forbearance
Issuance of RWI warrants in connection with forbearance
Reclassification of warrants from liability classified to equity classified
Accounting Policies [Abstract]
Nature of Business
Summary of Significant Accounting Policies
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities
Inventory Disclosure [Abstract]
Inventory
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets
Property, Plant and Equipment [Abstract]
Property and Equipment, Net
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities
Debt Disclosure [Abstract]
Debt
Leases
Leases
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Equity [Abstract]
Equity
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation
Revenue from Contract with Customer [Abstract]
Revenue Recognition
License And Distribution Agreements
License and Distribution Agreements
Retirement Benefits [Abstract]
Benefit Plan
Income Tax Disclosure [Abstract]
Income Taxes
Segment Reporting [Abstract]
Segment Information
Related Party Transactions [Abstract]
Related Party Transactions
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Use of Estimates
Fair Value Measurements
Cash and Cash Equivalents
Restricted Cash
Inventory
Property and Equipment
Impairment of Long-Lived Assets
Asset Acquisitions
In-Process Research and Development
Goodwill
Warrant Liabilities
Leases
Short-Term Debt- Yorkville
Revenue Recognition
Cost of Revenues
Research and Development Costs
Advertising and Marketing Costs
Government Grants
Patent Costs
Stock-Based Compensation
Comprehensive Income (Loss)
Income Taxes
Net Income (Loss) per Share
Segment Information
Allowance for Credit Losses
Concentrations of Credit Risk and Significant Customers
Emerging Growth Company
Reclassifications
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements
Schedule of Property and Equipment Estimated Useful Life
Schedule of Basic and Diluted Net Income Loss Per Share
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Schedule of Financial Assets and Liabilities Measures at Fair Value
Schedule of Reconciliation of Contingent Consideration Obligations
Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants
Schedule of Fair Value of Liability Warrants
Schedule of Sponsor Warrants
Schedule of Convertible Note Valuation Model
Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis
Schedule of Reconciliation of Yorkville Debt Measured on a Measured Basis
Schedule of Yorkville Short-term Debt Valuation Model
Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis
Schedule of Major Classes of Inventories
Schedule of Inventory Reserves
Schedule of Prepaid Expenses and Other Current Assets
Schedule of Property and Equipment, Net
Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments
Schedule of Intangible Assets, Net
Schedule of Aggregate Amortization Expense Related to Intangible Assets
Schedule of Accrued Expenses and Other Current Liabilities
Schedule of Debt
Schedule of Lease Costs
Schedule of Cash and Non-cash Activity Related to the lease Liabilities
Schedule of Future Minimum Payments under Non-Cancelable Operating Leases
Summary of the Warrants
Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model
Schedule of Stock Option Activity
Schedule of Activity Related to RSU Stock-Based Payment Awards
Schedule of Stock-based Compensation Expense
Schedule of Disaggregated Revenue by Product And Services
Schedule of Changes in Deferred Revenue from Contract Liabilities
Schedule of Current and Deferred Tax Provision
Schedule of Reconciliation of the U.S federal statutory income tax
Schedule of Deferred tax assets and liabilities
Schedule of Unrecognized Tax Benefits
Schedule of Financial Information by Segment
Date of incorporation
Reverse stock split ratio
Area of building
Net operating loss
Net cash used in operating activities
Accumulated deficit
Unrestricted cash and cash equivalent
Debt outstanding
Debt outstanding
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Property and equipment expected useful lives
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]
Net (loss) income
Weighted average shares outstanding, basic
Weighted average dilutive stock options
Weighted average restricted stock units
Weighted average shares outstanding, diluted
Net (loss) income, basic
Net (loss) income, diluted
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Nature of Operation, Product Information, Concentration of Risk [Table]
Product Information [Line Items]
Indefinite-lived IPR&D
Operating segments
Goodwill impairment
Accounts receivable
Contracted storage periods
Pay over time for a period
Marketing and advertising expenses
Grant monies
Instrument-specific credit risk income
Accumulated other comprehensive income
Tax authority percentage
Business segments
Concentration percentage
Accounts receivable
Instrument-specific credit risk income
Income (loss) from allocated to warrants
Change In Accounting Principle Accounting Standards Update Adopted
Accounting Standards Update [Extensible Enumeration]
Change In Accounting Principle Accounting Standards Update Adoption Date
Change In Accounting Principle Accounting Standards Update Immaterial Effect
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets:
Cash equivalents – money market funds
Convertible note receivable
Total fair value assets
Liabilities:
Acquisition-related contingent consideration obligations
Contingent stock consideration
Short-term debt - Yorkville
Warrant liability - July 2023 Registered Direct Warrants
Warrant liability - April 2023 Registered Direct Warrants
Warrant liability - May 2022 PIPE Warrants
Warrant liability - Sponsor Warrants
Warrant liability - Public Warrants
Total fair value liabilities
Beginning balance
Net transfers into (out of) Level 3
Purchases, settlements and other net
Fair value adjustments
Ending balance
Fair value, Beginning Balance
May 2022 PIPE warrant issuance
April 2023 Registered Direct warrant issuance
July 2023 Registered Direct warrant issuance
Gain recognized in earnings from change in fair value
Fair Value, Ending Balance
Fair value, Beginning Balance
Fair Value, Ending Balance
Total
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Common share price
Exercise price
Warrant and right outstanding measurement input
Term (years)
Face value
Coupon rate
Stock price
Term (years)
Risk-free interest rate
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]
Business Acquisition, Contingent Consideration [Line Items]
Beginning balance
Fair value adjustments
Ending balance
Line of Credit Facility [Table]
Line of Credit Facility [Line Items]
Balance
Conversion of debt into common shares
Principal repayments
Issuance of convertible promissory note
Fair value adjustment through earnings
Fair value adjustment through accumulated other comprehensive income
Fair value adjustment through interest accrual
Balance
Common share price
Credit spread
Volatility
Term (years)
Discount yield
Fair value, assets, level 1 to level 2 transfers, amount
Fair value, assets, level 2 to level 1 transfers, amount
Fair value, assets, transfers into level 3, amount
Fair value, assets, transfers out of level 3, amount
Fair value of the warrant liabilities
Fair value of the warrant liabilities
Forbearance extend period
Increased total note payments
Initial note payment
Second note payment
Raw materials
Work in progress
Finished goods
Inventory, gross
Less: inventory reserves
Inventory, net
Beginning balance
Additions for obsolete inventory
Write-offs
Ending balance
Inventory, Current [Table]
Inventory [Line Items]
Inventory impairment charge
Schedule Of Prepaid Expenses And Other Current Assets
Prepaid clinical expenses
Prepaid insurance expense
Other
Prepaid expenses and other current assets
Property and equipment
Less: Accumulated depreciation and amortization
Property and equipment, net
Depreciation expense
Depreciation and amortization expense
Intangible Asset, Indefinite-Lived [Table]
Indefinite-Lived Intangible Assets [Line Items]
Balance at beginning of year
Goodwill impairment
Balance at beginning of year
Intangible Asset, Finite-Lived [Table]
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets
Estimated useful lives
Less: Accumulated amortization
Amortizable intangible assets, net
Acquired IPR&D product rights
Estimated useful lives
2024
2025
2026
2027
2028
Number of reporting units
Goodwill, impairment loss
Impairment of intangible assets
Accrued clinical trial expense
Accrued professional fees
Accrued wages, bonuses, commissions and vacation
Accruals for construction in progress
Accrued compliance fee
Other
Total accrued expenses
Maximum advance amount
Pre-paid advance period
Line of credit aggregate limitation amount
Pre-paid advance issued discount percentage
Annual interest rate
Line of credit increase in interest rate during period in event of default
Issuance of common stock minimum option price per share
Maximum percentage of common stock issued
Percentage of beneficial ownership limitation
Minimum number of shares of common stock purchase
Minimum required daily volume weighted average price
Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days
Redemption premium percentage if volume weighted average price is less than $0.75
Redemption premium percentage if volume weighted average price more than $0.75
Proceeds from pre-paid advance gross
Proceeds from pre-paid advance
Pre-paid advance maturity period
Debt conversion, principal amount
Debt conversion, accrued interest amount
Debt conversion, number of shares issued
Fair value of debt
Amount of monthly repayment
Percentage of premium principal amount
Debt instrument payment
Debt instrument payment remaining balance
Business days
Debt instrument payment partial payment
Repayments of short-term debt
Accrued interest
Debt instrument redemption premium
Share price per share
Payment on due
Common stock issued pursuant to short-term debt maturity extension, shares
Common stock issued pursuant to short-term debt maturity extension
Amount required for payment
Additional amount required for payment
Cash payment
Diem interest payment for each day
Issue of common stock
Issue of Debt
Original issue discount
Maturity date
Conversion price per share
Percentage of conversion on outstanding common stock
Principal amont
Debt instrument contribution amount
Default rate
Gross proceeds
Interest rate
Short-term debt
Other short term debt due to related party
Original issue discount
Debt instrument, interest rate, effective percentage in event of default
Warrants to purchase Class A common stock
Purchase price of per share
Share issued purchase price
Exercise per share price (in Dollars per share)
Debt instrument, covenant compliance description
Fall in cash and cash equivalents
Variable interest rate
Warrant expiration date
Discount
Interest rate
Discount on warrant amount
Issuance price percentage
Debt instrument default interest rate
Amortization of debt discount (Premium)
Percentage of changes in cash flow
Short-term debt - related parties
Percentage of partial liquidating damages on purchase price
Percentage of partial liquidating damages on subscription amount
Daily interest accruing rate
Debt instrument, unamortized discount
Schedule Of Lease Costs
Operating lease cost
Variable lease cost
Total operating lease cost
Short term lease cost
Schedule Of Cash And Non-cash Activity Related To Lease Liabilities
Operating cash flows from operating leases
Remaining year
Year one
Year two
Year three
Year four
Year five
Year four Thereafter
Year five Thereafter
Total lease payments
Less imputed interest
Total
Rent expense
Area of building
Option to renew lease term period.
Option to renew lease term period.
Initial monthly base rent.
Tenant improvement allowance
Reduction in line of credit
New line of credit
Base rental payments
Operating lease liability
Weighted average remaining lease term
Weighted average discount rate
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Contingent consideration
Payments for master subscription agreement
Payment subscription period
Exit or disposal costs
Litigation settlement, amount awarded to other party
Accrued research and development software
Costs related to straight line basis agreement
Upfront fee
Annual maintenance fee
Clinical and regulatory milestones
License agreement period
License agreement period
Settlement payment
Shares issued for piggyback registration rights
Sale of biomaterial products amount
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares
Expiration date
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Warrants per share, percentage
Warrants outstanding
Number Of warrants repriced
Common stock, voting rights
Percentage of shares required for voting
Purchase and sale of shares
Warrants to purchase aggregate shares
Aggregate purchase price
Net related cost
Reduction to additional paid in capital
Proceeds from issuance of private placement in additional paid in capital, net
Warrants and rights outstanding, expire date
Warrants and rights issued closing date
Fair value of the warrant liability
Reduced exercise price
Amended termination date description
Additional warrant liability
Number of warrants or rights outstanding
Aggregate offering price
Sales agents commission rate
Gross proceeds from issuance of common stock
Net proceeds from sale of common stock
Average price per share
Adjusted advance notice period
Premium paid for private placement purchase
Fair value of modified warrant, incremental expense
Proceeds from the exercise of warrants
Warrant term
Number of shares issued
Payments of stock issuance costs
Number of warrants repriced
Base salary
Sale of stock, maximum average daily traded amount (in percent)
Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days
Sale of stock, percentage based on volume weighted average price
Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days
Consideration shares of common stock
Cash due diligence fee
Commitment fee in shares
Common stock shares issued
Common stock shares outstanding
Proceeds from private placements
Fair value of warrant modification
Percentage of partial liquidating damages
Line of credit percentage
Risk-free interest rate
Expected term (in years)
Expected volatility
Expected dividend yield
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options beginning balance
Weighted Average Exercise Price, beginning balance
Weighted Average Contract Term
Aggregate Intrinsic Value
Options Granted
Weighted Average Exercise Price, Granted
Options Exercised
Weighted Average Exercise Price, Exercised
Options Forfeited/Expired
Weighted Average Exercise Price, Forfeited/Expired
Options ending balance
Weighted Average Exercise Price, ending balance
Options Vested and expected to vest
Weighted Average Exercise Price, Vested and expected to vest
Weighted Average Contract Term, Vested and expected to vest
Options Exercisable
Weighted Average Exercise Price, Exercisable
Weighted Average Contract Term Exercisable
Aggregate Intrinsic Value
Options Exercised
Aggregate Intrinsic Value
Aggregate Intrinsic Value Vested and expected to vest
Aggregate Intrinsic Value Exercisable
Options outstanding including awards
Number of Shares opening balance
Weighted Average Grant Date Fair Value, beginning balance
Number of Shares Granted
Weighted Average Grant Date Fair Value, Granted
Number of Shares Released
Weighted Average Grant Date Fair Value, Released
Number of Shares Forfeited
Weighted Average Grant Date Fair Value, Forfeited
Number of Shares ending balance
Weighted Average Grant Date Fair Value, ending balance
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense
Number of shares remaining available for future grant
Number of shares issued for future issuance automatic increase period
Percentage of shares issued from outstanding capital stock, maximum
Percentage of fair market value
Stock option, expiration period
Options vesting period
Weighted average grant-date fair value of stock options granted
Aggregate intrinsic value, stock option exercised
Estimated weighted-average amortization period
Estimated weighted-average amortization period
Vested options to acquire shares
Vested options to acquire per share
Stock option vesting
Number of shares remaining stock options forfeited
Vesting description
Stock based compensation
Reversed stock based compensation expenses
Vesting percentage
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Line Items]
Beginning Balance
Deferral of revenue
Recognition of unearned revenue
Ending Balance
Service agreement term
License agreement notice period
Deferred revenue
Supply and distribution agreement period
Supply and distribution agreement renewal term
Supply and distribution agreement non-renewal notice period
Discount percentage payment for invoices within ten days
Payment term net
Material breach contract terminated term
Supply and distribution agreement period
Outstanding invoice amount refused
Payment of option fee in cash
Issuance of common stock
Option fee expense
Option fee expense
Commercial license to dental products agreement renewal term
License fee expense
License fees payment period
License fee payment
Contributions made to the plan
Accrued amount but not made matching contribution to the plan
Federal
State
Total current income tax expense
Federal
State
Total deferred tax expense
Total expense from income taxes
Federal statutory income tax rate
State income taxes, net of federal benefits
Interest accretion expense
Change in valuation allowance
Mark to market warrant
Deferred true-up
Stock-based compensation
Impairment
Other permanent items
Effective income tax rate
Net operating loss carryforwards
Research and development tax credit carryforwards
Stock-based compensation expense
Startup costs
Intangible assets
Deferred revenue
Unicap
Imputed interest on contingent payments
Legal fee capitalization and amortization
Capitalized research and development
Other
Total deferred tax assets
In-process research and development
Total deferred tax liabilities
Valuation allowance
Net deferred tax liabilities
Balance beginning
Decrease related to current year tax provisions
Decrease related to current year tax provisions
Balance ending
Effective Income Tax Rate Reconciliation [Table]
Effective Income Tax Rate Reconciliation [Line Items]
Net operating loss carryforwards
Operating loss carryforwards expiration year
Tax credit carryforwards
Tax credit carryforwards expiration year
Valuation allowance increased amount
Unrecognized tax benefits
Schedule of Segment Reporting Information, by Segment [Table]
Segment Reporting Information [Line Items]
Net revenues
Gross profit
Direct expenses
Segment contribution
Indirect expenses
Loss from operations
Amortization
Total other
Cost of revenues (excluding amortization of acquired intangible assets)
Number of operating segments
Total assets
Related Party Transaction [Table]
Related Party Transaction [Line Items]
StatementEquityComponentsAxis.Axis [Axis]
Accrued expenses
Securities purchase agreement date
Unpaid base salary
Net proceeds from offerings of equity securities
Percentage of unpaid base salary
Percentage of base salary
Bonus program effective date
Annual rate of base salary
Bonus program effective date
Proceeds from PIPE financings
Loan interest rate
Related party description
Receive for month
RSUs one-time grant value
One-time cash bonus
Amount paid
Contribution made
Loan agreement
Warrants to purchase common stock
Number of shares holding
Beginning balance
Purchases settlements and other net
Ending balance
January 2024 Bridge Loan - Tranche #2 warrant issuance
Reclassification of warrants from liability classified to equity classified
Term to initial exercise date (years)
Total short-term debt - unaffiliated
Short-term debt - other
Total short-term debt - related parties
Total debt
Unearned revenue
Subsequent Event [Table]
Subsequent Event [Line Items]
Consideration paid for assets
Upfront payment
Monthly milestone payments
Prior payment to related party
Net sales percentage
Notes and purchaser warrants principal amount
Proceeds from notes and purchaser warrants
Bearing interest
Increase in bearing interest
Common stock par value
Gross proceeds
Floor price
Warrant outstanding term
Percentage of cash fee equal to aggregate proceeds
Percentage of non-accountable expense fee
Initial retainer fee
Reimbursement of legal expenses
Percentage of exercise price equal to offering price
Restricted Cash [Policy Text Block]
2017 Equity Incentive Plan [Member]
Operating leases rent expense.
Office Manufacturing And Laboratory Space [Member]
Legacy Celularity [Member]
Deferred tax assets capitalized research and development.
Deferred tax assets legal fee capitalization and amortization.
Reacquired Rights [Member]
Option to renew lease term period.
Deferred tax liabilities in process research and development.
Operating lease commencement date.
Reversed stock based compensation expenses.
Initial monthly base rent.
Acquired product rights.
United States Federal And State [Member]
Short Term Debt [Policy Text Block]
Warrants Liabilities [Policy Text Block]
Base rental payments.
Indefinite lived intangible assets amortization method.
License Royalty And Other [Member]
H L I Cellular Therapeutics [Member]
Legacy Celularitys [Member]
L L C And Anthrogenesis [Member]
Accrued compliance fee.
Palantir Technologies Inc [Member]
Master Subscription Agreement [Member]
Upfront fee.
Issuance of common stock minimum option price per share.
Percentage of beneficial ownership limitation.
Settlement and Release Agreement [Member]
DiscountpPercentage payment for invoices within ten days.
Minimum required daily volume weighted average price.
Number of shares issued for piggy back registration rights.
Required monthly payment if daily volume weighted average price is below stated price.
Material breach contract terminated term.
Redemption premium percentage if volume weighted average price is less than stated price.
Sale of biomaterial products amount.
Redemption premium percentage if volume weighted average price more than stated price.
Evolution [Member]
Evolution Agreement [Member]
Number of business segments.
Pre paid advance period.
Concentrations of Credit Risk and Significant Customers [Policy Text Block]
Emerging Growth Company [Policy Text Block]
Maximum percentage of common stock issued.
One Customer [Member]
Proceeds from lines of credit gross.
Customer Two [Member]
Commercial license to dental products agreement period.
Recently Adopted Accounting Pronouncements [Policy Text Block]
May Two Thousand Twenty Two Private Investment In Public Equity Warrants [Member]
Reduction to additional paid in capital.
Proceeds from issuance of private placement in additional paid in capital net.
Convertible note receivable.
Segment contribution.
Indirect expenses.
Contingent stock consideration.
Warrant liability registered direct warrants two.
Warrant liability registered direct warrants.
Warrant liability private investment in public equity warrants.
Warrant liability sponsor warrants.
Warrant liability public warrants.
Debt conversion original debt accrued interest amount.
Warrants and rights issued closing date.
Fair value net assets liability.
Reduced exercise price.
Percentage of premium principal amount.
Amended termination date description.
Debt instrument payment remaining balance.
Business days.
Fair value assets level one to level two transfers amount during period.
Fair value assets level two to level one transfers amount during period.
May 2022 Private Investment In Public Equity Warrants Modified [Member]
Dr Robert Hariri [Member]
Debt Instrument payment partial payment.
Securities Purchase Agreement Date.
Debt instrument payment.
Bonus program effective date.
Contingent consideration obligation.
Aggregate offering price.
At the Market Sales Agreement [Member]
Maximum percentage of sales commission from gross sales proceeds.
Debt instrument accrued interest.
Debt instrument redemption premium.
Gross proceeds from issuance of common stock.
Liabilities purchases settlements and other net.
Unpaid base salary.
Payment term net.
Liabilities fair value net transfers into level three.
Debt instrument amount required for payment on due
Securities Purchase Agreement [Member]
March Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]
Stock issued during period shares short term debt maturity extension.
Stock issued during period values short term debt maturity extension.
Debt instrument amount required for payment.
Additional debt instrument amount required for payment.
Stock issued during period common stock offering value.
Chairman And Chief Executive Officer [Member]
Private investment in public equity warrant issuance.
Gain loss recognized in earnings from change in fair values.
Registered direct warrants issuance.
Registered Direct Warrant Issuance During July.
Schedule Of Fair Value Of The Liability [Table Text Block]
Fair value of warrants.
License fees payment period.
Public Warrants [Member]
Sponsors Warrants [Member]
Payment Of Option Fee In Cash.
Adjusted advance notice period.
Percentage of unpaid base salary.
Percentage Of Base Salary.
Premium Paid For Private Placement Purchase.
Supply And Distribution Agreement Period.
Supply and distribution agreement renewal term.
Annual Rate Of Base Salary.
License agreement notice period.
Two Thousand Twenty Three Registered Direct Warrants [Member]
License fee expense.
Defined contribution plan accrued amount matching contribution not made.
Commercial license to dental products agreement renewal term.
Agreement termination date.
Outstanding invoice amount refused.
Option fee expense.
Base salary effective date.
Service agreement term.
Schedule Of Inventory Current And Noncurrent [Table Text Block]
Contract with customer liability increase decrease for contract from business combination and deferred revenue.
Inventory raw materials current and noncurrent.
Two Thousand And Twenty One [Equity Incentive Plan [Member]
Inventory work in progress current and noncurrent.
Inventory finished goods current and noncurrent.
Inventory gross current and noncurrent.
Share based compensation arrangement by share based payment award number of shares issued for future issuance automatic increase period.
Dr Hariri [Member]
Laboratory And Production Equipment [Member]
Machinery Equipment And Fixtures [Member]
Warrant expiration term
Prepaid Expenses And Other Current Assets Disclosure [Text Block]
Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]
Two Thousand And Twenty One And Two Thousand And Seventeen Equity Incentive Plan [Member]
Awards With Performance Conditions [Member]
Awards With Market Conditions [Member]
Prepaid clinical expense.
Stock Issued During Period Shares For Interest Payable.
Schedule Of Activity In Inventory Reserves [Table Text Block]
Inventory reserve current and noncurrent.
Inventory reserve for obsolescence additions.
May Two Thousand Twenty Three Private Investment In Public Equity Warrants [Member]
Schedule of Estimated Useful Lives [Table Text Block]
Stock issued during period shares warrants exercise.
Inventory Impairment Charge.
Due To Lower Of Cost Or Market Adjustments For Finished Goods [Member]
Due To Lower Of Cost Or Market Adjustments For Work In Progress Goods [Member]
Inventory net current and noncurrent.
Cumulative effect adjustment.
Stock issued during period shares of common stock in registered direct offering net of offering expenses.
Debt Instrument Per Diem Interest Amount.
Common stock issued pursuant to shortterm debt maturity extension value.
Common stock issued pursuant to shortterm debt maturity extension shares.
Stock issued during period shares of research and development.
Schedule Of Fair Value Significant Inputs For Warrants Issued [Table Text Block]
Convertible Promissory Notes [Member]
Equity Purchase Agreement [Member]
Dragasac Warrant [Member]
Sponsor Warrants [Member]
Convertible Promissory Note Discount Percentage.
Percentage of conversion on outstanding common stock.
Tax withholding on vesting of restricted stock units.
Tax withholding on vesting of restricted stock units shares.
March Two Thousand Twenty Three Loan Warrants [Member]
Loan Agreement [Member]
March Two Thousand Twenty Three Private Investment in Public Equity Warrants, Modified [Member]
Debt Instrument, Contribution Amount.
Issuance of common stock in pipe offering net of offering expenses shares.
April Two Thousand Twenty Three Registered Direct Warrants [Member]
Ceo Promissory Note [Member]
June Two Thousand Twenty Three Loan Warrants [Member]
June Two Thousand Twenty Three Warrants [Member]
July Two Thousand Twenty Three Registered Direct Warrants [Member]
Vesting of restricted stock units.
Vesting of restricted stock units shares.
Warrants Per Share Percentage.
Issuance of warrants on senior secured bridge loans.
Warrants Outstanding.
Adjustments to additional paid in capital issuance of warrants on senior secured bridge loans.
Consulting Agreement [Member]
Dr Andrew Pecora [Member]
Number Of Warrants Repriced.
C V Starr Co Inc [Member]
Debt Instrument Original Issue Discount.
Receive For Month.
Non Cash Lease Expense.
Debt Instrument, Interest Rate, Effective Percentage in Event of Default.
Provision for Inventory Obsolescence.
Scientific And Clinical Advisor Agreement [Member]
Inventory impairment.
January Two Thousand Twenty Four PIPE Warrants [Member]
Two Thousand Twenty Four Warrant Repricing [Member]
Acquired In-process Research And Development.
Issuance of Common Stock for Stem-cells to Be Used in Research and Development.
Issuance Of Common Stock Relating To Debt Extension.
Discounts Arising From R W I Loan Arrangement Related Party.
May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrant [Member]
Fair Value Of Warrant Modification For Professional Services.
Fair Value Of Warrant Modification For Professional Services.
Accrued Research & Development Software.
Increase Decrease In Right Of Use Assets And Lease Liabilities.
Proceeds From Issuance of Senior Secured Bridge Loan and Warrants Related Party.
Proceeds From Issuance of Senior Secured Bridge Loan and Warrants Related Party.
Fall In Cash And Cash Equivalents.
Proceeds from the sale of common stock in Atm offering.
Robin L Smith Md [Member]
Advisory Agreement [Member]
Payments Of At The Market Offering Costs And Commissions.
Proceeds From Other Short Term Debt Related Party.
GX Sponsor Warrants [Member]
Related Party Base Salary.
Schedule Of Convertible Note Valuation Model Table [Text Block]
Forbearance Agreement [Member]
Face Value Of Notes Receivable.
Related party cash bonus.
Payments To Related Party.
Percentage of coupon rate.
RWI Forbearance Agreement [Member]
Class of warrant or righst expiration date.
Chief Administrative Officer [Member]
Amended Employment Agreement [Member]
Valuation Model That Relate To Sanuwave Common Stock.
COTA Inc [Member]
Tranche Two Warrant [Member]
Valuation input for a convertible promissory note term.
Cryoport Systems Inc [Member]
Valuation input for a convertible promissory note.
Share Issued Purchased Price.
Issuance of warrants on senior secured bridge loan.
Initial Loan [Member]
Reduction of right of use assets and associated lease liability due to lease modification.
Debt instrument discount.
PIPE related costs included in accrued expenses.
Interest accrued on senior secured loans within long term debt related parties.
Forbearance extend maturity period.
Sanuwave Forbearance Agreement [Member]
Letter Agreement [Member]
Reclassification of option liabilities to equity.
Debt instrument interest rate during period in event of default.
Increased note payments.
Additional Loan [Member]
Supply and distribution agreement non renewal notice period.
Initial note payment.
Second note payment.
Fair Value Assets Of Contingent Stock Consideration Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]
Sale of stock maximum average daily traded amount percentage.
Contingent Stock Consideration [Member]
Statement Equity Components Axis .
Promissory notes receivable.
Accrued research and development software.
Other short term debt.
Cell Therapy [Member]
Degenerative Disease [Member]
Other short term debt due to related party.
April Two Thousand Twenty Three Registered Direct Warrants Modified [Member]
Effective income tax rate reconciliation interest accretion expense.
Effective income tax rate reconciliation deferred true up.
Florham Park New Jersey [Member]
Deferred tax assets tax credit carryforwards research and development.
Schedule Of Intangible Assets Net [Table Text Block]
Deferred tax assets startup costs.
Second Tranche [Member]
Deferred tax assets unicap.
Deferred tax assets imputed interest on contingent payments.
Reduction in line of credit.
New line of credit.
Biovance 3L [Member]
Tax credit carryforwards expiration year.
Contracted storage periods.
Payment plans for customer to pay over time period.
Cash And Non Cash Activity Related To Lease Liabilities [Table Text Block]
Operating loss carryforwards expiration year.
License And Distribution Agreements [Text Block]
Regeneron Research Collaboration Services Agreement [Member]
Arthrex Agreement [Member]
Change in fair value of contingent consideration liability.
Reduction of research and development expense resulting from grant.
Operating income costs and expenses.
Government Grants [Policy Text Block]
Patent Costs [Policy Text Block]
Accrued clinical trial expense.
Change in fair value of debt.
Other nonoperating income expenses.
Accruals for construction in progress.
Payments for master subscription agreement.
Instrument specific credit risk income.
Accumulated other comprehensive income to other expense upon short term debt conversion.
Minimum percentage of recognized tax benefit likelihood of being realized upon ultimate settlement with tax authority.
Software Cease Use Costs [Member]
Yorkville [Member]
Pre Paid Advance Agreement [Member]
License Agreement [Member]
Annual maintenance fee.
Clinical and regulatory milestones.
Pre paid advance issued discount percentage.
Line of credit increase in interest rate during period in event of default.
Sale of stock maximum average dailyTradedAmountThresholdConsecutiveTradingDays
Contingent stock consideration obligation.
Sale of stock percentage based on volume weighted average price.
Loan agreement.
CV Star Loan [Member]
Discount on warrant amount.
Sale of stock lowest daily volume weighted average price threshold consecutive trading days.
Fair Value Assets Of Yorkville Debt Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block]
Sale of stock consideration commitment fee in shares.
Sale of stock consideration cash due diligence fee.
Fair value measurement with unobservable inputs reconciliation conversion of debt into common shares.
Fair value measurement with unobservable inputs reconciliation fair value adjustment through interest accrual.
Resorts World Inc Pte Ltd [Member]
Tranche One Warrant [Member]
Schedule of yorkville Short Term Debt Valuation Model [Table Text Block]
Unrestricted cash and cash equivalents.
Sorrento Therapeutics Inc [Member]
Ms Hariri [Member]
Employment Of Immediate Family Member [Member]
Number of shares holding.
Valuation input for short term debt dividend yield.
Valuation input for short term debt term.
Valuation input for short term debt share price.
Valuation inputf or short term debt.
Valuation input for short term debt discount yield.
Minimum number of shares of common stock purchase.
Valuation input for short term debt credit spread.
Short term debt related parties.
Effective income tax rate reconciliation mark to market warrant.
Biobanking [Member]
Warrant liability.
Asset Acquisitions [Policy Text Block]
Area of building.
In process research and development impairment.
Operating lease expiry year.
Initial Tranche [Member]
Payment subscription period.
Stock issued during period shares reclassification of previously exercised stock options.
Issuance of common stock shares for debt extension and commitment fee.
Adjustments to additional paid in capital issuance and modification of warrants.
Issuance of common stock value to palantir as consideration for settlement agreement.
Stock issued during period value reverse stock splits.
Fair value measurement with unobservable inputs reconciliation convertible promissory note.
Twenty Twenty One Plan [Member]
Adjustments to additional paid in capital reclassification of warrants from liability classified to equity classified.
2021 And 2017 Plan [Member]
Bridge loan and warrant issuance tranche two.
Reclassification of warrants from liability classified to equity classified.
Issuance of common stock shares to palantir as consideration for settlement agreement.
January Two Thousand Twenty Four Bridge Loan Tranche Two Warrants [Member]
Issuance of common stock for debt extension and commitment fee.
Warrants and rights outstanding term to initial exercise date.
Issuance of common stock to Palantir as consideration for settlement agreement.
Issuance of common stock relating to debt extension and commitment fee.
Non cash interest expense.
Proceeds from sanuwave convertible note.
Proceeds from warrants and short term debt related parties.
Repayments of short term debt unaffiliated.
Proceeds from short term debt unaffiliated
Payment of sepa commitment fee.
Repayments of short term debt related party.
Modification of CV starr warrants in connection with forbearance.
Issuance of rwi warrants in connection with for bearance.
Reclassified from warrant liability to additional paid in capital.
Instrument specific credit risk loss.
Unearned revenue.
Income loss from allocated to warrants.
Customer One [Member]
Goodwill Impairment.
Cell Therapy Clinical Trial Update [Member]
Short term debt unaffiliated.
CV Starr Bridge Loan Net Of Discount [Member]
Issuance Price Percentage.
Market Condition Stock Unit [Member]
Percentage of changes in cash flow.
Percentage Of Partial Liquidating Damages On Purchase Price.
Initial And Second Tranche [Member]
Net sales percentage.
Percentage of partial liquidating damages on subscription amount.
Daily Interest Accruing Rate.
Monthly milestone payments
Unsecured Senior Convertible Notes [Member]
Lessee operating lease liability payments due after year four.
Sequence Lifescience Inc [Member]
Upfront payment
Stock issued during period value reclassification of previously exercised stock options.
Stock issued during period shares reclassification of previously exercised stock options.
Fair Value Of Warrant Modification Incremental For Equity Issuance Cost.
Investor Rights Agreement [Member]
Dragasac Limited [Member]
Prior payment to related party.
Notes and purchaser warrants principal amount.
Proceeds from notes and purchaser warrants.
Minimum gross proceeds.
Additional warrant liability.
Floor price.
Percentage of cash fee equal to aggregate proceeds.
Percentage of non accountable expense fee.
Initial retainer fee.
Reimbursement of legal expenses.
Proceeds from private placements.
Percentage of exercise price equal to pffering price.
Change in fair value of contingent stock consideration.
Stock issued during period value warrants exercised.
Stock issued during period common stock commissions and offering value.
Stock issued during period value of common stock in registered direct offering net of offering expenses.
Stock issued during period value of research and development.
Issuance of common stock in pipe offering net of offering expenses.
Stock issued during period of issuance of common stock under atm agreement.
Stock issued during period common stock commissions and offering shares.
Stock issued during period of issuance of common stock under atm agreement shares.
Stock issued during period shares warrants exercised.
Other [Member]
Debt instrument default interest rate
January 2024 Bridge Loan Tranche One Warrants [Member]
Percentage of shares required for voting.
Pulthera Llc Binding Term Sheet [Member]
Customer A [Member]
License Agreement With Biocellgraft Inc [Member]
License fee payment.
Proceeds from issuance of private placement net.
March 2024 Rwi Forbearance Warrants [Member]
Starr Forbearance Agreement [Member]
Software cease use costs.
Debt
May Two Thousand Twenty Three Private Investment In Public Equity Warrant [Member]
May Two Thousand Twenty Two Private Investment In Public Equity Warrant [Member]
May Two Thousand Twenty Two Private Investment in Public Equity Warrants And April Two Thousand Twenty Three Registered Direct Warrants [Member]
Fair value net assets liabilities.
Short-term debt - related parties.
Useful Life, Shorter of Lease Term or Asset Utility [Member]
Assets, Current
Liabilities, Current
Liabilities
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
OperatingIncomeCostsAndExpenses
Operating Income (Loss)
Other Nonoperating Expense
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Equity, Attributable to Parent
Shares, Outstanding
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent
VestingOfRestrictedStockUnits
Impairment of Intangible Assets (Excluding Goodwill)
Employee Benefits and Share-Based Compensation
IssuanceOfCommonStockForStemCellsToBeUsedInResearchAndDevelopment
FairValueOfWarrantModificationForProfessionalServices
Increase (Decrease) in Other Operating Assets and Liabilities, Net
IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
AccruedResearchDevelopmentSoftware
Increase (Decrease) in Contract with Customer, Liability
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Property, Plant, and Equipment
ProceedsFromSanuwaveConvertibleNote
Payments to Acquire in Process Research and Development
Net Cash Provided by (Used in) Investing Activities
PaymentsOfAtTheMarketOfferingCostsAndCommissions
RepaymentsOfShortTermDebtUnaffiliated
PaymentOfSepaCommitmentFee
RepaymentsOfShortTermDebtRelatedParty
Payment, Tax Withholding, Share-Based Payment Arrangement
Payments of Debt Issuance Costs
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Capital Expenditures Incurred but Not yet Paid
IssuanceOfWarrantsOnSeniorSecuredBridgeLoan
ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital
Inventory Disclosure [Text Block]
Lessee, Operating Leases [Text Block]
Inventory, Policy [Policy Text Block]
Goodwill and Intangible Assets, Policy [Policy Text Block]
Lessee, Leases [Policy Text Block]
Revenue from Contract with Customer [Policy Text Block]
Compensation Related Costs, Policy [Policy Text Block]
Income Tax, Policy [Policy Text Block]
Segment Reporting, Policy [Policy Text Block]
Debt [Default Label]
Goodwill, Impairment Loss, Net of Tax
Accounts Receivable, Allowance for Credit Loss
InstrumentSpecificCreditRiskLoss
Assets, Fair Value Disclosure
Liabilities, Fair Value Disclosure
ContingentConsiderationObligation
Fair Value, Net Asset (Liability)
ValuationInputForConvertiblePromissoryNoteTerm
ContingentStockConsiderationObligation
ValuationInputForShortTermDebtSharePrice
ValuationInputForShortTermDebtTerm
InventoryGrossCurrentAndNoncurrent
InventoryReserveCurrentAndNoncurrent
InventoryNetCurrentAndNoncurrent
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
GoodwillImpairment
IndefiniteLivedIntangibleAssetsAmortizationMethod
Other Accrued Liabilities, Current
Accrued Liabilities, Current
StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension
StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension
DebtInstrumentOriginalIssueDiscount
DebtInstrumentInterestRateDuringPeriodInEventOfDefault
Lease, Cost
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
OperatingLeaseExpiryYear
OperatingLeaseCommencementDate
SaleOfStockLowestDailyVolumeWeightedAveragePriceThresholdConsecutiveTradingDays
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-Based Payment Arrangement, Expense
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Contract with Customer, Liability
Deferred Revenue
AgreementTerminationDate
CommercialLicenseToDentalProductsAgreementPeriod
Current Income Tax Expense (Benefit)
Deferred Federal Income Tax Expense (Benefit)
Deferred State and Local Income Tax Expense (Benefit)
Deferred Federal, State and Local, Tax Expense (Benefit)
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Deferred Income
Deferred Tax Assets, Other
Deferred Tax Assets, Gross
DeferredTaxLiabilitiesInProcessResearchAndDevelopment
Deferred Tax Liabilities, Gross
Deferred Tax Assets, Valuation Allowance
Deferred Tax Liabilities, Net
Operating Loss Carryforwards
BaseSalaryEffectiveDate
ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified